Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)

#2104

Introduction: Metastatic GEP-NET G1/G2 incurs large costs on the Swedish health care system.

Aim(s): To describe direct costs since time of diagnosis, for patients with metastatic GEP-NET G1/G2 in Sweden.

Materials and methods: Data was obtained via linkage of nationwide registers. Patients diagnosed between 1Jul2005 and 31Dec2007 in Sweden and with a follow-up of at least six years were included (n=115). Health care costs and pharmacological costs (SSA, interferon-alpha [IFN], chemotherapy, and targeted therapies) were assessed.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Granfeldt D, Björstad A, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, cost-of-illness, somatostatin analogues,